134
Participants
Start Date
May 25, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2027
Nanoliposomal irinotecan
In the control arm (Naliri) a dose of 70mg/m² is administered in combination with 5FU and leucovorin In the investigational arm (Nalirinox) a dose of 50mg/m² is administered in combination with 5FU, leucovorin and oxaliplatin
5 FU
In the control arm (Naliri) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan and leucovorin In the investigational arm (Nalirinox) a dose of 2400 mg/m² is administered in combination with nanoliposomal irinotecan, leucovorin and oxaliplatin
Leucovorin
In the control arm (Naliri) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan and 5FU In the investigational arm (Nalirinox) a dose of 400 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and oxaliplatin
Oxaliplatin
Only administered in the investigational arm (Nalirinox): a dose of 60 mg/m² is administered in combination with nanoliposomal irinotecan, 5FU and Leucovorin
RECRUITING
ULB Erasme, Brussels
RECRUITING
Cliniques Universitaires Saint-Luc UCL, Brussels
RECRUITING
AZ Turnhout, Turnhout
RECRUITING
UZ Antwerpen, Antwerp
RECRUITING
CHC MontLégia, Liège
RECRUITING
Pôle Hospitalier Jolimont (HELORA), Haine-Saint-Paul
NOT_YET_RECRUITING
AZ St-Lucas, Bruges
RECRUITING
AZ Imelda, Bonheiden
RECRUITING
Grand Hopital de Charleroi, Charleroi
RECRUITING
AZ Maria Middelares, Ghent
RECRUITING
University Hospital Ghent, Ghent
RECRUITING
CHU Ambroise Paré, Mons
RECRUITING
CHR Namur, Namur
University Hospital St Luc, Brussels
OTHER
Belgian Group of Digestive Oncology
OTHER